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Abstract 
Objectives. To estimate the healthcare resources spent by diabetic patients in Spain during the 
year 2002. 
Methods. The present work is a cost-of-illness study. Direct healthcare costs were estimated 
using rates of DM, based on primary and secondary sources of information. A range of 
prevalence from 5% to 6% of the adult population was determined. The total cost was composed 
of six items: insulin and oral hypoglycemic agents; other drugs; disposable and consumable 
goods (glucose test strips, needles and syringes); hospitalization; primary care visits; visits to 
specialists.  
Results. The estimated direct cost of DM during the year 2002 ranges from € 2.4 billion to € 2.67 
billion. Hospital costs had the highest weight (€ 933 million) in the total, followed by non-insulin, 
non-hypoglycemic-agent drugs (€ 777-932 million). Much lower are the costs of insulin and oral 
hypoglycemic agents (€ 311 million), primary care visits (€ 181-272 million), specialized visits (€ 
127-145 million) and disposable elements (€ 70-81 million). The per-diabetic, per-year cost 
ranges between   € 1,290 to € 1,476. 
Discussion. Despite our rather conservative approach to the issue, our findings demonstrate the 
high direct healthcare costs of diabetic patients. Likewise, they illustrate the magnitude of the 
costs of treatment of DM-related complications. 
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1. Background 
 
Diabetes Mellitus (DM), in its two Types, 1 and 2, is a high-incidence, chronic, globally-
occurring disease that increases morbidity and mortality, seriously diminishing quality of life. 
 
The World Health Organization´s (WHO) estimated that in 1995 135 million adults were 
suffering  from the disease. WHO´s forecasts for the year 2025 raise that figure to 300 
million people (a 120% increase) ( 1).  Every day more resources are allocated to DM 
prevention and treatment, but at the same time its prevalence grows  steadily. In 1987,  
2.2% of USA's healthcare expenditures were consumed by diabetic  patients. Five years 
later, in 1992, the percentage had more than doubled (to 5.8%), and 2.8% of the population 
was suffering diabetes (2, 3)  
 
A diabetic patient may suffer acute decompensations, such as diabetic ketoacidotic state. 
He/she may develop as well chronic complications such as cardiovascular problems, renal 
disease and loss of vision. The risk of suffering these conditions is higher for DM people 
compared to non-diabetics people in the same age group. (4, 5, 6).   
 
About 50% of all deaths of Type 1 diabetic  patients are related to acute myocardial 
infarction; another 15% are related to  strokes (cerebrovascular disease) (7, 8). A 25% of all 
diabetics have foot ulcers (“diabetic  foot”) and peripheral vascular disease. One in 15 
diabetics will suffer inferior limb amputation during his or her lifetime and among these,  30-
40% will lose the other limb within the following 3 years (9, 10), placing DM as the main 
cause of non-traumatic amputation. On the other hand, the prevalence of diabetic  
nephropaty reaches 30-40% among Type 1 diabetic  patients; for Type 2 diabetics it is lower 
(17-30%) (7), but still significant. It is estimated that 23% of people undergoing hemodyalisis 
in Spain suffer from diabetes (11). Diabetic  retinopathy is the main cause of blindness in 
people younger than 60, causing 20-30% of all cases of blindness in developed countries. In 
Spain, the prevalence of blindness has been estimated at 5-6% among diabetics, having 
been calculated that they are six times more likely to lose their vision than the general 
population.  In a recent study,  Morato et al (12), estimate that DM Type 2 patients have the 
following rates of complications: Retinopathy: 33%; Peripheral vascular disease: 21%; 
Nephropathy: 17%; Cerebrovascular disease: 10%; Coronary disease: 14%; Peripheral 
neuropathy: 40%;  Autonomic neuropathy: 20%. When diabetes was diagnosed, 52% of 
diabetics already suffered some sort of complication.  
Chronic complications are the main cause of death among diabetic  patients, and are 
responsible for the highest costs both in hospitalization and drugs. It is estimated that the 
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costs of drugs for chronic diabetes complications are 2.5 times higher than those of the 
general population, even after adjusted by age. Moreover, even leaving aside the cost of 
insulin and oral hypoglycemic agents, the resources spent  on other drugs are higher among 
diabetics than for the general population ( 13,  14,  15). Given the relevance of chronic DM 
complications, cost-of-illness studies based only on acute complications of the disease result 
in underestimations (3, 16-26). A key aspect of the present study is to identify not only the 
direct costs of treating DM itself, but also the consumption of resources to prevent and treat 
complications. 
 
Despite the abundance of cost-of-illness and cost-effectiveness studies in the specialized 
international literature, in Spain only three studies have tried to measure the direct 
healthcare costs of DM.  Hart et al. (27) concluded that the total costs associated to DM in 
1994 were around €544.8 million, an average annual cost of €381 per diabetic. 
Hospitalization costs represented the main portion of all costs, accounting for 36% of the 
total, followed by doctor and hospital out- patient visits (14.1%), antidiabetic  drugs (13.2%), 
lab tests (10%) and dialysis (9.4%). 
 
The CODE-2 study (28) analyzed the direct healthcare cost of a sample of 1004 type 2 
diabetes patients. The mean annual cost per patient was €1,304. This represents a total 
annual cost for Spain of €1.96 billion. In this case, the biggest percentage of expenditures 
went to drugs (42.4%, including oral antidiabetic agents, insulin and other drugs), followed 
by hospitalization (32%) and ambulatory care (25.6%). 
 
Finally, López Bastida et al. (29)  considered DM direct and indirect costs in the Canary 
Islands. Their findings show that the  direct healthcare costs attributable to DM were €24.02 
million, or €470.23 per known diabetic patient per year (62% of the total cost of a diabetic 
patient). This percentage includes the costs of drugs and hospitalizations, and, lagging 
further behind, primary care visits , visits to specialists and laboratory  tests. The indirect 
cost was, according to the study, €14.77 million, or 38% of the total cost. 
 
López Bastida's work has some obvious advantages. First of all, data were provided directly 
by the Canary Islands Health Service and are truly primary ones. Furthermore,  the study 
estimated the indirect costs of DM. However, since the study was conducted in a part of the 
country where DM prevalence is by far higher than the national average, it is difficult to 
extrapolate to Spain as a whole.  
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Only three studies of DM costs in Spain, with varying methodology, and international findings 
difficult to apply to our country given national differences in prevalence, healthcare systems, 
methodologies and relative prices, leave room for new research. This is why this paper's 
goal is to estimate the healthcare costs of patients with DM, including costs of chronic 
complications, using the primary or secondary information available.  
 
 
2. Methodology and results 
 
The study focuses on  the prevalence of DM and is aimed at estimating the direct healthcare 
costs of diabetics during the year 2002. Both a total cost and a per-patient cost are 
estimated.  
 
In order to determine the number of diabetics in Spain, we analyzed the most recent 
epidemiological data available for prevalence and selected the interval 5%-6% (30-43).  The 
variety of sources, methodologies and estimations made difficult to select only one value. 
The minimum value we have considered, 5%, is that of the 1997 National Health Survey 
(Encuesta Nacional de Salud) (42) taking into account adult people (18 years and older) who 
reported they were diabetics, or had high blood-sugar levels, or said they used antidiabetic  
drugs. In other recent studies, the prevalence was near 6% or even higher 32, 40, 41, 43). 
The chosen thresholds of prevalence are rather conservative, in any case, given that it is 
well-established that a significant percentage of diabetics are not diagnosed (44, 32) and the 
prevalence of DM is increasing. Another assumption is that 90% of diabetics were 
considered Type 2 and 10% Type 1 (44). 
 
The rate of prevalence determines the average annual cost per patient. The total cost of 
some important items (e.g. hospitalizations, insulins or oral hypoglycemic agents) obtained 
from primary sources is not influenced by the chosen prevalence.   
 
5 
 
2.1. Drugs  
 
Figures regarding the total costs of insulin (Subclass A10A) and oral hypoglycemic agents 
(Subclass  A10B) were obtained directly from data bases ALHAQUEM and RHAZES  and  other 
publications from the General Directorate of Pharmacy of the Ministry of Health (45,46).  All 
National Health System outpatient prescriptions are included in these data bases. Costs for 
2002 were estimated by applying the average historical growth rate to the 1992-2001 data. 
 
Drugs consumed by diabetics are not only the above-mentioned subclasses. They consume 
other medications to prevent or treat complications associated with DM. Age-adjusted 
consumption of hypolipemiants, antihypertensives and platelet antiaggregating drugs is 
significantly higher in diabetics than in the general population (28, 17, 19). Figures for non-
insulin, non-oral hypoglycemic drugs come from the CODE-2 study (28) updated for the year 
2002.  
 
2.2. Consumable goods: test strips, needles and syringes  
 
The costs of test-strips were calculated using data from the four available sources. The first 
is INSALUD (Instituto Nacional de la Salud) (primary source) the central government agency 
that provided health care in Spain. It has been decentralized to the regional governments. 
36% of Spanish population (slightly more than 14 million people) was still cared for by 
INSALUD up until the end of 2001. On the first of January 2002 devolution of health care to 
the regions was completed. Clua et al. and Olveira and Carral (47, 48, 18) are secondary 
sources of information. 
 
The pattern of use and the costs of needles and syringes were drawn from Costa (49, 50). 
We assume that only Type 1 diabetic  patients use these items, a hypothesis that may be 
somehow conservative granted that a number of DM Type 2 patients are treated with insulin  
and need these items as well.  
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2.3. Visits to specialist and dialysis  
Turning to costs of out-patient (ambulatory) visits to specialists, we relied on the following 
information 
- Expertise from the department of analytical accountancy of the Hospital of Getafe on 
the items to be considered. 
- Secondary sources (29,51)  
- Data from INSALUD (52) on cost per visit in a Section of Endocrinology 
 
This heading includes: 
 
- Costs of service, including personnel, rents, materials, power, water and sanitation; 
healthcare goods and drugs. 
- Costs of other services, including infrastructure, personnel, board and catering, 
customer service, booking, admissions, archives of clinical records, pharmacy,  blood 
extraction, biochemistry, hematology lab, microbiology, nuclear medicine, pathology , 
radiology, endoscopy and neurophisiology.  
- Other structural costs. 
 
Another cost item is expenditures on dialysis for diabetic  patients. The prevalence of 
diabetics under dialysis was obtained from  Amenaber et al.  (11). 
 
It should be noted that there is no information about visits to specialists other than 
endocrinologists (such as neurologists, cardiologists, ophthalmology,…). For this reason, we 
do not include them in our analysis.  
 
 
2.4. Primary care visits 
 
In this case, data were obtained from secondary sources. López Bastida et al. (29) found 
that the frequency of primary-care visits was eleven per patient, per year for diabetic  
patients on insulin, and nine for those on oral hypoglycemic agents or diet only. Clua et al. 
(47, 48) findings indicate that the frequency of visits per patient, per year was ten in the area 
they analyzed.  
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No primary data about costs per visit in primary care are available. We reviewed previous 
works published in Spain on the topic and found wide variation among different authors (27, 
61, 62, 63, 64, 65, 66, 67). Therefore we drew on the mid-range values.  
 
2.5. Hospital costs 
 
To calculate hospital costs we relied on the Conjunto Mínimo Básico de Datos - CMBD (Set 
of Minimum Basic Data) (60). The CMBD has been developed following the 
recommendations of the European Minimum Basic Data Committee and it compiles useful 
information starting from clinical records and discharge reports from public and private 
hospitals. It collects the following data: clinical record number, patient's age and sex, main 
and secondary diagnoses, date of hospitalization and discharge, and procedures performed, 
using the International Classification of Diseases (ICD-9-CM), where DM has the main code 
250. After the first classification, each patient is assigned to a  Diagnosis-Related Group 
(DRG). The CMBD recovers main and secondary diagnoses - an important detail, because it 
improves the detection of diabetics who are hospitalized for causes other than acute DM 
complications. We selected all hospitalizations where the diagnosis was DM. When a 
diabetic patient is hospitalized due to a decompensation related to diabetes, he or she is 
included in either DRGs 294 or 295; if the cause of hospitalization is a chronic complication, 
the patient is grouped according to the primary disease, that is, DM. In this way, by grouping 
DRGs by disease, all chronic DM related complications are taken into account (see table 1).  
( INSERT TABLE 1) 
 
 
From the above mentioned primary and secondary sources, we estimated the direct 
healthcare cost of diabetic patients in Spain. Other direct costs, like special diets, 
educational programs, visits to specialist nurses or emergency rooms services  were not 
considered. All figures are updated to the year 2002 applying the  annual Spanish inflation 
rate, unless otherwise specified. 
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3. Results 
 
According to data from the General Directorate of Pharmacy of the Ministry of Health, the 
total cost of insulin and oral hypoglycemic agents (A10A and A10B subclasses) was €  
311.43 million.  
 
A large part of DM Type 2 expenditures are due to drugs other than insulin or oral 
hypoglycemic agents. These costs have been estimated  at € 424.44 per patient per year 
(for 1999) (28). In general, age-adjusted DM Type 1 patients' drug expenditures are 
substantially higher than those of DM Type 2 patients. Nonetheless, the average age of DM 
Type 1 patients is lower, making it plausible that their average drug consumption could be 
similar even without age adjustment. We assumed, therefore, that the average cost of 
non-insulin, non-oral hypoglycemic drugs was similar in DM Type 1 and Type 2 patients. 
Considering a 5% prevalence in the adult population (1,675,304 people), the cost of those 
drugs was € 777.0 million. Assuming a 5.5% prevalence (1,842,835 people), the costs would 
be € 854.7 million. Finally, if prevalence in the adult population was 6% (2,010,365 people), 
the resulting cost would be € 932.4 million. 
 
INSALUD's expenditures in test strips reached € 23.86 million during 2002. Extrapolating 
this figure for the whole Spanish population ( 36% of Spaniards were covered by INSALUD 
in 2000), the result is € 66.82 million in 2000. Updating the sum to the year 2002, the figure 
would be € 70.89 million (Hypothesis A). A previous study (18) estimated that 1.3% of the 
Spanish population, or 531,016 people, used test strips to determine blood glucose levels. 
The per capita annual cost in 1997 was estimated at €103.6 (48). Adjusting that figure to 
2002 and assuming a constant percentage of users, the estimated cost for 2002 is € 66.87 
million (Hypothesis B). If we expand the second assumption, and suppose that test-strip 
users have climbed to 1.5% of the population (615,593 people), the estimated cost for 2002  
rises to € 77.52 million (Hypothesis C).  
 
( INSERT TABLE 2) 
 
According to Costa et al (49, 50),  the daily cost of needles and syringes ranges between is 
€ 0.051 to € 0.0535. Using those figures as a bottom line and applying our estimated 
prevalence, the total annual cost of needles and syringes for 2002 would range between € 
3.22 million and €  4.04 million. 
 
In order to estimate the costs of visits to endocrinologists, our starting assumption was that 
between a third and a half of all visits to endocrinologists are due to DM (51). The 
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subsequent-visit to first-visit ratio is 4 to 1. The cost of first visits (52)  was € 79.4 (updated to 
2002), whereas the cost of subsequent visits was € 47.6.  In one year, first visits range 
between 127,691 and 191,537, and the annual number of subsequent visits range between 
510,764 and 766,146. These figures would result in an estimated cost ranging from € 34.46 
million to € 51.69 million. 
 
Amenabar et al. report the prevalence of dialysis in Spain on Dec. 31, 2000 (11): 441 
patients per million undergoing hemodyalisis and 41 per million undergoing peritoneal 
dialysis. The same report identifies DM as the main cause of renal failure, responsible for 
23% of patients on dialysis during the year 2000. Therefore, in Spain 17,363 patients are 
annually in hemodyalisis and 1,614 undergo peritoneal dialysis. The total of diabetics in 
dialysis was 3,994 and 371, respectively, in the year 2000. The total annual cost of dialysis 
in diabetic patients was € 93 million in 2002, being € 21,308 the mean annual cost per 
treatment (61) (€ 19,500 in 1999, adjusted to 2002). 
 
The frequency of primary care visits was estimated - rather conservatively (29, 47, 48) - at 
an average of nine per year. According to the prevalence rate considered, the total number 
of primary care visits may fluctuate between 15 and 18 million annually. Due to the wide 
dispersion of costs estimated for primary care visits in Spain, we used an average of the 
intermediate values found in recent literature. These values range between €12 (Hypothesis 
A) and €15 (Hypothesis B) per visit. Under these assumptions, the estimated cost ranges 
from a minimum of €181.24 million (prevalence: 5%; mean cost per visit: €12) and €271.86 
million (prevalence: 6%; mean cost per visit: €15), finding in-between values for the other 
assumptions.  
 
Finally, using the CMBD (60) we estimated hospital costs of diabetic patients. We found 
285,013 hospitalizations of diabetic patients, a little more than three million stays. The total 
cost was estimated by applying the mean tariff per DRG per case. For 1999, the total 
estimated cost of stays related to patients with "Diabetes Mellitus” in their diagnoses (main 
or secondary), was €853.74 million. Adjusting that figure  to 2002  the estimated cost rises to 
€ 932.99 million.  
 
The relative weight of acute DM complications was 4.7% of the total hospital costs of 
diabetic patients. The fraction of hospital costs due to chronic complications was 37.4% 
(32.2% attributable to macrovascular problems and 5.2% due to microvascular). The 
remaining 57.8% was caused by other hospitalizations apparently unrelated to DM.  
  
(INSERT TABLE 3) 
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4. Conclusion 
 
Aggregating the previously mentioned items results in a direct yearly healthcare cost that 
fluctuates between a minimum of € 2.4 billion and a maximum of € 2.67 billion. These 
figures, in terms of annual average costs per diabetic, are € 1,290 and € 1,476 as the lowest 
and highest values, respectively (see table 4). It is important to highlight that this is the first 
time that the CMBD and ALHAQUEM and RHAZES  data bases are used to estimate the 
cost of patients with diabetes in Spain.  
 
(INSERT TABLE 4) 
 
Regarding the distribution of these costs, hospitalization and drugs are the most important 
items. Hospital costs fluctuate -depending on the assumptions involved- between 35% and 
39% of the total. Expenditures on insulin and oral hypoglycemic agents range from 12% to 
13%, while the cost of other drugs is  between 31% and 36%. The cost of primary care visits 
trail far behind, varying from  8% to 10% of the total. The cost of visits to the endocrinologist 
and dialysis are 5%  to 6%, whereas the cost of test strips, needles and syringes amount to 
3% to 4% of the total (see figures). 
 
(INSERT FIGURES) 
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5. Discussion 
 
It has been estimated that, nowadays, the diabetic population consume at least around 5%-
6% of the global health care expenditures in developed countries (3), and a diabetic patient 
consumes at least three times more direct resources (physicians´ services, drugs, 
hospitalizations) that a non-diabetic.  
 
For the prevalence interval above mentioned, the direct health care costs of DM patients in 
Spain for 2002 was between 5% to 5.5% of total medical expenditures. That is, between 5% 
to 6% of the population are diabetic patients and consume nearly € 2.4-2.7 billion. Other 
attempts to determine the costs of diabetic patients in Spain have not include all relevant 
costs. In this paper we have tried to identify and quantify the direct medical costs for 2002, 
capturing all available data bases in the National Health System. 
 
Several limitations of this study must be recognized. The figures for prevalence and costs 
are estimations that need some qualifications. First, DM prevalence is probably higher than 
the figures we used, since a significant number of DM cases among the general population 
go undiagnosed (30-44). It could affect our average cost per patient, with total costs almost 
unchanged since they were obtained mainly from primary sources and official accounting 
records measuring resources spent in DM independently of the number of patients treated.  
Only our estimations of “cost of other drugs” and  “cost per visit in primary care" depend 
directly on the chosen prevalence rate.  
 
Secondly, the hospital cost figures are essentially a conservative estimation of the real cost 
of diabetics. The reason is that the CMBD relies upon a tariff for each DRG. In spite of this, 
several studies show that for identical DRG the average cost of diabetics is higher than the 
average costs of non-diabetic  patients (62, 72, 73, 74). Therefore, the hospital costs related 
to non acute complications – chronic complications and other hospitalizations -  of diabetic  
patients must be actually higher than the figures we have used. The phenomenon has a 
simple explanation: diabetes makes treating any other disease more expensive since it is a 
factor that extends hospital stays. This also makes diabetics more expensive than 
non-diabetic patients, independent of the episode that caused the hospitalization. The 
CMBD  corroborates this, showing differences in the length of stay for diabetics and non-
diabetics in the 590 identified DRGs, even after age is factored out. Other international 
studies reflect similar differences between the age-adjusted mean length of stay for identical 
DRGs among DM and non-diabetic patients (14, 16, 66, 67).   
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Finally, we did not include costs for all possible healthcare items. Specifically,  the number of 
visits  to specialists other than endocrinologists is unknown. In Spain  the quality of data on 
drugs (insulins and oral hypoglycemic agents) and hospitalizations is solid.  However, no 
homogeneous databases exist at present for ambulatory care (primary or specialized). 
 
The relative weight of different items is similar to the findings of other studies (3, 6, 8, 14, 20, 
21, 22), being the main item hospital costs. However, many papers omit data on drugs other 
than insulins and oral hypoglycemic agents. Polypharmacy is a frequent phenomenon 
among diabetics and becomes widespread  with age and the evolution of the disease over 
time. Almost every DM patient requires not only hypoglycemic treatment, but also treatment 
for comorbidities and cardiovascular risk factors linked to DM. In fact, if we add up the 
aggregate costs of insulins, oral hypoglycemic agents and other drugs, plus costs of 
consumable goods, their total value would surpass hospital costs (49% vs. 35% for 6% 
prevalence) (see figures).  
 
Expenditures for all drugs and consumable goods range between a minimum of € 1.16 and a 
maximum of € 1.3 billion. It represents 48-49% of the total cost, nearly 15% greater than 
hospital costs. It should be noted, however, that the relative incidence of each item should 
be considered rather cautiously, given the above mentioned information and data problems.  
 
It also should be underlined that the present work does not include non-healthcare direct 
costs,  neither indirect costs (productivity loss) nor informal care costs faced by patients and 
society as a whole. Estimations of indirect costs are not so frequent and findings diverge 
anywhere from 30% to 55% of total costs (2, 3, 6, 8, 13, 20, 21, 24, 26, 68, 69, 70). Similarly, 
intangible costs connected to DM were not included. In chronic diseases these costs are 
often significant, but quantifying them is very complex (they are seldom calculated and 
quality of life is used as a proxy).  
  
Cost of illness studies are subject to criticism around three ideas: (71)  
 
1. The total cost of the disease is not what really matters. The point is what can be done 
to mitigate or prevent and what resources are needed. 
2. Estimating total costs of DM is useful as a means of measuring the benefits of 
prevention and treatment only if interventions really prevent or cure diseases 
(marginal analysis). 
3. The fact that costs are larger does not imply that greater benefits will be achieved by 
allocating more resources to the disease with higher costs. 
 
13 
 
Resources should not be allocated according to the costs of a certain disease, but rather 
where interventions benefit the most. But it is true that cost of illness studies help to illustrate 
the real dimension of health problems. Cost of illness studies are suited to reveal the 
economic repercussions of a given disease, quantifying healthcare and other resources 
spent that could be allocated to alternative goals. They also provide society and 
decision-makers valuable information about the relative and absolute impact of health 
problems, helping, therefore, to set priorities in the use of healthcare and social resources 
(72).  
 
In this article we have highlighted the relevance of prevention and treatment of chronic 
complications related to DM. Our more striking finding is that drugs and consumable goods, 
including other drugs different from hypoglycemic agents, account for 48-49% of the total 
health care costs of diabetic patients. In previous studies hospital costs were the largest 
portion, mainly due to hospital treatment of chronic diabetes-related complications. Since 
almost all diabetic patients will undergo treatments to prevent and to treat cardiovascular risk 
factors and macrovascular complications, the preventive management of diabetes and 
chronic complications should become an imperative. The cost of preventive treatment is 
insignificant compared with the downstream costs of treating inadequately or not treating the 
disease. Now  the challenge is how to allocate resources more efficiently being the main 
goal to increase the life-span and quality of life of diabetics. 
 
This study is another piece of evidence to support that well-proven effective medical 
procedures (73-78), good health education, appropriate self-care by patients and good 
coordination among healthcare levels, is the best combination to achieve high standards of 
cost-effectiveness and cost-utility (79-81) and ultimately extend life and improve the quality 
of life for diabetics.  
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Table 1 
 
Clinical  
classification 
International 
Classification of 
Diseases (ICD-9-CM) 
Diagnosis-Related Group  (DRG) 
Hyperglycemic 
episode 
250.0-250.2 294-566 
Ketoacidosis 250.1-250.3 295  
Neuropathy 250.6 6-18-19 
Nefropathy 250.4                
(581.81-583.81) 
304-305-315-316-317-320-321-
322-331-332-556-568-569 
Ophtalmopathy 250.5                
(362.01-362.02) 
36-37-39-42-45-46-47 
Peripheral Vascular 
Disease  
250.7 
440.9-443.8-785.4 
113-114-124-130-131-209-225-
269-270-285-292-796 
Cerebrovascular 
Disease 
250.7 
430-437-438 
5-14-15-16-17-532-533 
Cardiovascular 
Disease 
250.7 
410-411-412-413-414-
414.8 
106-107-112-120-121-122-123-
124-125-127-132-133-134-140-
141-142-144-145-478-479-544-
546-549-550-808 
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Table 2. Cost of test strips 
 
 Hypothesis A Hypothesis B Hypothesis C 
Cost of test strips 
(millions of €) 
70.89 
 
66.87 
 
 
77.52 
 
Hypothesis A: INSALUD data extrapolated to the whole Spanish population 
Hypothesis B: (18) and  (48) 
Hypothesis C: (18) and (48) plus increase in percentage of users. 
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Table 3. Synthesis of Hospital Activity 
 Hospitalizations Stays Estimated Cost 
1. Acute complications 6.8% 5.4% 4.7% 
2. Chronic complications 38.1% 36.9% 37.4% 
         2.1 Microvascular complications 8.1% 4.9% 5.2% 
          2.2 Macrovascular complications 30.0% 32.0% 32.2% 
3. Other hospitalizations 55.2% 57.7% 57.8% 
Source: CMBD  
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Table 4 
Synthesis 
Costs of Diabetes Mellitus Patients In Spain, 2002 
 
 
Prevalence: 5%   
of adult 
population 
Prevalence: 5.5% 
of adult 
population 
Prevalence: 6% 
of adult 
population 
Number of people with DM 1,675,304 1,842,835 2,010,365 
Cost of insulins (A10A) and                                 
oral hypoglycemic agents (A10B) (*) 311.43 311.43 311.43 
Other drugs 777.00 854.70 932.40 
Consumable goods                                                
(test strips + needles and syringes) 70.09-80.74 70.41-81.06 70.73-81.38 
visits to specialists  + dialysis (*) 127.46 -144.69 127.46 - 144.69 127.46 - 144.69 
Primary care visits 181.24- 226.55 199.36 - 249.20 217.49-271.86 
Hospital costs (*) 932.99 932.99 932.99 
  Total cost 
Minimum total cost 2400.21 2496.35 2592.49 
Maximum total cost 2473.40 2574.07 2674.75 
 
Minimum per-patient cost 1432.70 1354.63 1289.56 
Maximum per-patient cost 1476.39 1396.80 1330.48 
In millions of euros, except population and per-patient figures 
 
(*) In these items, estimated costs do not depend on DM prevalence, because they come 
from records and primary sources (see methodology). 
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Costs unit: millions of euros 
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Costs of DM patients: maximun cost (prevalence = 6%)
Out-patient costs
16%
In-patient costs
35%
Cost of drugs and 
consumable goods
49%
Costs of DM patients: minimum cost (prevalence = 5%)
Cost of drugs and 
consumable goods
48%
In-patient costs
39%
Out-patient costs
13%
